Bearz, A., Martini, J., Jassem, J., Kim, S., Chang, G., Shaw, A., . . . Solomon, B. (2023). Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4: :ALK Variant Type and ALK With or Without TP53 Mutations.
Citação norma ChicagoBearz, A., et al. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4: :ALK Variant Type and ALK With or Without TP53 Mutations. 2023.
Citação norma MLABearz, A., et al. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4: :ALK Variant Type and ALK With or Without TP53 Mutations. 2023.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.